| Document |
Document Title |
|
WO/2022/108068A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/105845A1 |
A glucoside derivative, and a preparation method therefor and an application thereof. Specifically, provided is a glucoside derivative, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The ...
|
|
WO/2022/108141A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/101352A1 |
The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.
|
|
WO/2022/103031A1 |
Provided is a triazine or pyrimidine derivative that contributes to a substantial improvement in lifespan of an organic electroluminescent element by effectively absorbing high energy in the UV range from an external light source to mini...
|
|
WO/2022/102992A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2022/100624A1 |
A new compound effectively antagonizing LPAR. The new compound is a compound represented by the following formula, or is a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug of the compound represented b...
|
|
WO/2022/100623A1 |
Disclosed is a new class of compounds that effectively antagonize LPAR, which are compounds represented by the following formula, or a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compounds r...
|
|
WO/2022/099011A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...
|
|
WO/2022/094354A1 |
The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of prep...
|
|
WO/2022/092141A1 |
The present invention provides: a compound, or a pharmaceutically acceptable salt thereof, having an antiviral activity and represented by formula (I); and a pharmaceutical composition containing the same. (In the formula, the broken lin...
|
|
WO/2022/092625A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a composition for an organic layer of an organic light-emitting device, and a method for ma...
|
|
WO/2022/092638A1 |
Provided is a pyrimidin derivative substantially contributing to the driving voltage, efficiency and extended life of an organic electroluminescent device. The organic electroluminescent device according to the present invention comprise...
|
|
WO/2022/088865A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic apparatus. The nitrogen-containing compound has a structure as represented...
|
|
WO/2022/092180A1 |
To solve a food crisis associated with an increase in world population expected in the near future, the creation of novel herbicides having high safety for crops and excellent herbicidal activity against weeds is desired. The problem is ...
|
|
WO/2022/089428A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element and an electronic device. The structure of the nitrogen-containing compound is as shown in fo...
|
|
WO/2022/082817A1 |
The present invention relates to a 3-three-membered spirooxindole derivative synthesizing method, comprising: in a protective atmosphere and an organic solvent, using a 3-indoleethanol compound as a reaction raw material, and carrying ou...
|
|
WO/2022/083598A1 |
The present application relates to the technical field of organic materials, and specifically disclosed therein are a nitrogen-containing compound and an electronic element and electronic apparatus using same, the nitrogen-containing com...
|
|
WO/2022/084168A1 |
The present invention relates to 4,6-difluorodibenzothiophene derivatives of formulae I-1 and I-2, to a process for the preparation thereof, to liquid-crystalline (LC) media comprising these derivatives and to electro-optical devices and...
|
|
WO/2022/084280A1 |
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" rep...
|
|
WO/2022/080651A1 |
The present specification relates to: a heterocyclic compound of chemical formula 1; and an organic light-emitting device and an organic material layer forming composition, which comprise same.
|
|
WO/2022/078428A1 |
Provided are a compound as a prolyl hydroxylase inhibitor and a preparation method therefor, which belong to the technical field of medicines. The compound is shown in formula I, has a prolyl hydroxylase inhibitory activity, and can be u...
|
|
WO/2022/078306A1 |
The present invention relates to the technical field of organic synthesis and chemical catalysis. Disclosed are a large steric hinderance palladium-nitrogen-heterocyclic carbene complex, a preparation method for same, applications of sam...
|
|
WO/2022/080927A1 |
The present invention relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/081807A1 |
The present invention provides acyl sulfonamide compounds of general formula (I): in which R1, R2, R3, R4, R5, R6ยท Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for pre...
|
|
WO/2022/075566A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2022/076764A1 |
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...
|
|
WO/2022/076496A1 |
Invented are compounds of formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula (I), pharmaceutical compositions comprisi...
|
|
WO/2022/075601A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/073904A1 |
This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
|
|
WO/2022/076495A1 |
Invented are compounds of Formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising c...
|
|
WO/2022/076627A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases,...
|
|
WO/2022/075787A1 |
The present invention relates to a pharmaceutical composition for preventing or treating diseases related to mitochondrial dysfunction, comprising a novel quinone derivative as an active ingredient, and provides a composition for prevent...
|
|
WO/2022/074214A1 |
A process for the preparation of compound of formula I is provided: Formula (I) where R1 and R2 are as defined in the description.
|
|
WO/2022/071484A1 |
The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also...
|
|
WO/2022/072975A1 |
In one aspect, the disclosure relates to viral papain protease inhibitors, methods of making the same, pharmaceutical compositions comprising the same, and methods of treating and/or preventing COVID-19 and other coronavirus diseases usi...
|
|
WO/2022/068772A1 |
A compound related to formula (I), a preparation method therefor, and the use thereof in medicine. Specifically, provided are a compound related to formula (I) or a stereoisomer, a tautomer and a pharmaceutically acceptable salt thereof....
|
|
WO/2022/067724A1 |
Provided are an SGLT-2 inhibitor sarcosine co-crystal, a preparation method therefor and use thereof. Using sarcosine as a ligand, said co-crystal has higher safety and lower costs; a drug co-crystal has higher stability, and during the ...
|
|
WO/2022/065762A1 |
The present specification relates to: an organic light-emitting device comprising a first electrode, a second electrode, and one or more organic layers provided between the first electrode and the second electrode, wherein at least one o...
|
|
WO/2022/065761A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic material layer.
|
|
WO/2022/065730A1 |
Provided is a cyano group-substituted aryl or heteroaryl derivative which effectively absorbs high-energy light in the UV region from an external light source to minimize damage to organic materials inside an organic electroluminescent d...
|
|
WO/2022/063317A1 |
Disclosed are a fused tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/061193A1 |
Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in ...
|
|
WO/2022/058327A1 |
The present invention relates to compound of formula (I): wherein the variables are defined as in claim 1, to compositions comprising at least one of said compounds and at least one agriculturally suitable auxiliary, to the use of said c...
|
|
WO/2022/057930A1 |
The present invention relates to the technical field of medicines. Disclosed are a benzimidazole compound having an endothelial lipase inhibition effect, and an application. The benzimidazole compound of the present invention has an exce...
|
|
WO/2022/060036A1 |
The present invention provides a novel compound capable of improving the light-emitting efficiency, stability, and lifespan of an element, an organic electronic element using same, and an electronic device comprising same.
|
|
WO/2022/060812A1 |
This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
|
|
WO/2022/060020A1 |
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light-...
|
|
WO/2022/061348A1 |
Provided herein are SOS1 protein degraders, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of ...
|
|
WO/2022/055169A1 |
The present invention relates to a compound for an organic optoelectronic element, represented by chemical formula 1, a composition for an organic optoelectronic element, the composition including the compound, an organic optoelectronic ...
|
